Shopping Cart
Remove All
Your shopping cart is currently empty
Pirmitegravir
Copy Product Info
🥰Excellent
Catalog No. T39755Cas No. 2245231-10-9
Alias STP0404
Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC. Pirmitegravir inhibits PBMC.Pirmitegravir has significant antiviral activity and may be useful in the study of HIV virus infection.
Pirmitegravir
Copy Product Info🥰Excellent
Purity: 99.79%
Catalog No. T39755Alias STP0404Cas No. 2245231-10-9
Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC. Pirmitegravir inhibits PBMC.Pirmitegravir has significant antiviral activity and may be useful in the study of HIV virus infection.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $136 | In Stock | In Stock | |
| 5 mg | $338 | In Stock | In Stock | |
| 10 mg | $546 | In Stock | In Stock | |
| 25 mg | $1,090 | In Stock | In Stock | |
| 50 mg | $1,790 | In Stock | In Stock | |
| 100 mg | $2,390 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.79%
ee:99.4%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC. Pirmitegravir inhibits PBMC.Pirmitegravir has significant antiviral activity and may be useful in the study of HIV virus infection. |
| Targets&IC50 | CEMx174 cells:1.4 nM, HIV-1:0.41 nM |
| In vitro | In CEMx174 cells, Pirmitegravir demonstrates an IC50 of 1.4 nM, inhibiting dual tropic HIV-189.6[1]. Pirmitegravir is a highly potent ALLINI, inhibiting both wild-type and Ral-resistant HIV-1 strains, with IC50 values ranging from picomolar to single-digit nanomolar[1].With an IC50 of 0.41 nM against HIV-1NL4-3, Pirmitegravir exhibits no observable cytotoxicity in human PBMCs at 10 μM (TC50 >10μM)[1]. |
| In vivo | For once-daily administration, Pirmitegravir exhibits appropriate PK profiles[1]. The lack of micronucleus-inducing and bone marrow cell proliferation inhibitory potentials in rats (500, 1000, and 2000 mg/kg/day) supports the conclusion that Pirmitegravir is not genotoxic[1].An assessment of the Pharmacokinetics (PK) profile of Pirmitegravir in rat and dog has been conducted[1]. |
| Synonyms | STP0404 |
| Molecular Weight | 495.01 |
| Formula | C27H31ClN4O3 |
| Cas No. | 2245231-10-9 |
| Smiles | [C@@H](OC(C)(C)C)(C(O)=O)C=1C(=C2C(N(CC=3C=NN(C)C3)C(C)=C2C)=NC1C)C4=CC=C(Cl)C=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (111.11 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Pirmitegravir | purchase Pirmitegravir | Pirmitegravir cost | order Pirmitegravir | Pirmitegravir chemical structure | Pirmitegravir in vivo | Pirmitegravir in vitro | Pirmitegravir formula | Pirmitegravir molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.